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Abstract 
Background: Extensive studies investigating the role of host genetic factors during malaria associate glucose-
6-phosphate dehydrogenase deficiency with relative protection. G6PD deficiency had been reported to associate 
with anti-malarial drug induced with haemolytic anaemia.
Methods: A total of 301 Gabonese, Ghanaian, and Kenyan children aged 6–120 months with severe malaria recruited 
in a multicentre trial on artesunate were included in this sub-study. G6PD normal (type B), heterozygous (type A+) and 
deficient (type A−) genotypes were determined by direct sequencing of the common African mutations G202A and 
A376G. Furthermore, multivariate analyses were executed to associate possible contributions of G6PD deficiency with 
baseline haemoglobin levels, parasitaemia and with severe malarial anaemia.
Results: Two hundred and seventy-eight children (132 females and 146 males) were successfully genotyped for 
G6PD variants. The overall prevalence of G6PD deficiency was 13 % [36/278; 3 % (4/132) female homozygous and 
22 % (32/146) male hemizygous], 14 % (40/278) children were female heterozygous while 73 % (202/278) were G6PD 
normal [67 % (88/132) females and 78 % (114/146) males] individuals. Multivariate regression revealed a significant 
association of moderately and severely deficient G6PD genotypes with haemoglobin levels according to the baseline 
data (p < 0.0001; G6PD heterozygous: p < 0.0001; G6PD deficient: p = 0.009), but not with severe malarial anaemia 
(p = 0.66). No association of G6PD genotypes with baseline parasitaemia.
Conclusions: In this study, moderately (type A+) and severely (type A−) G6PD deficiency showed significant asso-
ciation with lower haemoglobin concentrations at baseline in African children with severe malaria without leading 
to severe malarial anaemia. In addition, there was no association of G6PD variant types with parasite densities on 
admission.
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Background
Malaria remains a major health problem, with approxi-
mately 3.2 billion people at risk. In 2015, WHO reported 
approximately 214 million cases and about 438,000 
deaths occurring in the world with the highest morbidity 
and mortality rates observed in Africa, especially among 
children under 5 years of age [1]. The control of the dis-
ease particularly in low transmission settings is the key 
target for malaria elimination [2] but such success is still 
a great challenge [3]. One approach to reduce the disease 
incidence is to block the transmission. Primaquine, a 
8-aminoquinoline effective for both transmission block-
ing of Plasmodium falciparum and anti-relapse treatment 
against Plasmodium vivax has been recommended for 
many years by the World Health Organization (WHO) 
[4, 5]. However, primaquine has a major drawback which 
limits its widely use. The drug is known to cause acute 
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haemolytic anaemia in individuals with glucose-6-phos-
phate-dehydrogenase (G6PD) deficiency [6, 7].
G6PD is a key enzyme catalysing the first reaction in 
the pentose phosphate pathway and provides a reduced 
form of nicotinamide adenine dinucleotide phosphate 
(NADPH) to help cells to counterbalance oxidative stress 
[8]. G6PD deficiency is a common, X-linked hereditary 
enzyme deficiency affecting approximately 400 million 
people worldwide [9], mainly in malaria-endemic regions 
[10]. Among the 186 mutations identified until 2012 in 
the G6PD gene [11], the variants 376A (G6PD type B), 
376G (G6PD deficiency type A+ and 202A (severe G6PD 
deficiency type A−) are the most common ones. The defi-
ciency types A+ (moderately deficient) and A− (severely 
deficient) constitute up to 90  % of reported G6PD vari-
ants [8, 12, 13]. Other mutations such as A542T, G680T 
or T968C have also been identified in parts of Africa 
and been suggested to contribute to G6PD deficiency. 
However, information available on these mutations is 
very scarce. For example, the T968C mutation has been 
reported to be common only in The Gambia [14] and 
Senegal [15]. Although, G6PD diagnostic enzyme tests 
are available, they are currently not widely used in most 
clinical studies, particularly because primaquine, is not 
regularly used in Africa. Any attempts to control malaria 
need to take into account also tertian malaria, which, 
although occurring rarely only in many parts of Africa, 
contributes to the world-wide malaria burden.
Previous case–control studies have reported an asso-
ciation of G6PD deficiency, in particular of the 202A 
variant, with an increased risk of severe malarial anaemia 
and a protection or reduced risk against cerebral malaria 
[16, 17]. Therefore, it is interesting to assess the influence 
of this allele on the clinical presentation of severe malaria 
among the African children recruited into this study.
This study was a sub-study of a multicentre trial of 
artesunate conducted by the “Severe Malaria in Afri-
can Children” (SMAC) consortium which assessed the 
non-inferiority of a simplified 3-dose regimen of intra-
muscular and intravenous artesunate [18]. The aim was 
to determine using direct sequencing the frequency dis-
tribution of G6PD deficiency in malaria children from 
Africa. Some exploratory analyses have also been per-
formed to investigate the effect of G6PD genotypes on 
asexual parasitaemia, haemoglobin concentrations and 
severe malarial anaemia during admission.
Methods
Study design and participants
This study was a sub-study of the SMAC follow-up 
study. The SMAC study was an open-label, randomized, 
multicentre (Gabon, Malawi, Ghana, Kenya, and The 
Gambia), parallel-group, three-arm study to compare 
the anti-malarial activity and safety of three artesunate 
(ARS) dosing regimens in children with severe P. falci-
parum malaria. Patients were randomly assigned to one 
of three dosing regimens consisting of a total of 12 mg/
kg parenteral ARS: (i) 2.4 mg/kg intramuscular on admis-
sion and at 12, 24, 48 and 72 h, (ii) 4 mg/kg intramuscular 
on admission and at 24 and 48 h, and (iii) 4 mg/kg intra-
venous on admission and at 24 and 48 h post admission. 
Parasitaemia was assessed by thick blood smears at 6  h 
intervals and prior to the each dose of treatment for at 
least 48 h following the first dose of study drug. Malaria 
occurs holoendemically and transmission rates in all 
study countries are high and perennial.
The present study involved participants of the SMAC 
study from Gabon, Ghana and Kenya. Three hundred and 
one children aged 6–120  months with a diagnosis of P. 
falciparum infection (parasitaemia  ≥5000 parasites/µL 
on initial blood smear) made using an alternative to con-
ventional thick film examination (Lambaréné method) 
[19] were randomly selected from the SMAC follow-up 
study [18]. Blood samples (400 μL) from all participants 
were collected in heparinized tubes. Specimens were 
stored at −80 °C for subsequent molecular analyses.
Ethics statement
The study was conducted in accordance with Good 
Clinical Practices, and approved by authorities for each 
study site (the Regional Ethics Committee in Lambaréné 
(CERIL) for Gabon, Committee on Human Research, 
Publication and Ethics, Kwame Nkrumah University of 
Science and Technology (KNUST), Kumasi, for Ghana 
and the National Ethics Research Committee, Kenya 
Medical Research Institute (KEMRI) for Kenya). Chil-
dren were enrolled into this study if a parent or guard-
ian was willing to provide written informed consent in 
accordance with local practice.
G6PD genotyping
Genomic DNA was isolated using QIAamp DNA mini 
blood kit (Qiagen, Hilden, Germany). A 968  bp frag-
ment of the G6PD gene containing the polymorphisms 
202G  >  A and 376A  >  G was amplified by PCR using 
primers 5′-GCCCCTGTGACCTCCCGCCA-3′ (for-
ward) and 5′-GCAACGGCAAGCCTTACATCTGG-3′ 
(reverse). The main focus was directed only to these two 
variants although some other deficient genetic mutations 
such as A542T (Senegal 1 %, The Gambia 2.2 %), G680T 
(The Gambia 0 %, Senegal 0 %) and T968C (The Gambia 
7.8 %, Senegal 10 %) have been reported at a substantially 
lower prevalences only [14, 15], and might have been 
present in this study population. However, they seem 
not to be responsible for the prevalence of G6PD defi-
ciency in all parts of Africa [20]. Briefly, 10 ng of genomic 
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DNA were added to a 20 µL reaction mixture containing 
1 × PCR buffer (20 mM Tris–HCl pH 8.4, 50 mM KCl, 
1.5 mM of MgCl2), 0.125 mM of dNTPs, 0.25 mM of each 
primer and 1 U Taq DNA polymerase (Qiagen, Hilden, 
Germany). The PCR was run on a PTC-200 Thermal 
cycler (MJ Research, Waltham, USA). Thermal conditions 
after initial denaturation (94 °C, 5 min) were 35 cycles of 
94 °C for 45 s, 65 °C for 1 min, and 72 °C for 1 min. PCR 
reactions were completed with a final extension step of 
72  °C for 5  min. PCR products were visualized through 
electrophoresis on a 1.2 % agarose gel stained with SYBR 
green I in 1x Tris-electrophoresis buffer (90  mM Tris–
acetate, pH 8.0, 90 mM boric acid, 2.5 mM EDTA).
Subsequently, PCR products were purified (Exo-SAP-
IT, USB, Affymetrix, USA) and directly used as templates 
for DNA sequencing using the BigDye terminator v. 1.1 
cycle sequencing kit (Applied Biosystems, Foster City, 
USA) on an ABI 3130XL DNA sequencer. G6PD poly-
morphisms were identified by assembling the sequences 
with the reference sequence of G6PD (NG_009015.2) 
gene using the Codoncode Aligner 4.0 software (http://
www.codoncode.com) and visually reconfirmed from 
their electropherograms.
Statistical analysis
Data were analysed by using GraphPad Prism v. 5.0 for 
windows (GraphPad software, San Diego, CA). The effect 
of G6PD genotypes was determined on initial parasitae-
mia and haemoglobin values using a multivariate regres-
sion model. The children were classified in groups of 
normal, intermediate (female heterozygous) and deficient 
(hemizygous males and homozygous females) individu-
als. To evaluate the effect of G6PD genotypes on haemo-
globin concentrations, the model included adjustment 
for age, gender, centre, weight, temperature and parasi-
taemia. To investigate the G6PD effect on parasitaemia, 
parasite densities were log-transformed and the model 
included adjustment for age, gender, centre, weight, hae-
moglobin levels and temperature. For the construction 
of the multivariate regression model, a subjective model-
building approach that excludes possible confound-
ers such as gender, age and origin of study participants 
was applied. Kruskal–Wallis of One-way ANOVA with 
Dunn’s Multiple Comparison and Mann–Whitney tests 
were used to determine the differences among categories. 
The level of significance was set to a P value of 0.05.
Results
Patients
According to the SMAC definition of severe malaria 
which perfectly reflects the policies of most African 
hospitals [21, 22], the frequency of severe malaria syn-
dromes at presentation were substantially different across 
the three study sites (Table  1). The majority of children 
fulfilled one or more criteria of the WHO definition 
of severe malaria [23, 24], which include severe anae-
mia (haematocrit of  <15  % or Hb  <5  g/dL with a para-
sitaemia of >10,000/μL), hyperlactataemia (≥5 mmol/L), 
hyperparasitaemia (>250,000 parasites/μL), hypoglycae-
mia (whole blood or plasma glucose ≤2.2 mmol/L), and 
haemoglobinuria (urine that is dark red or black, with a 
dipstick that is positive for Hb/myoglobin). A description 
of children screened, recruited and genotyped for their 
G6PD status is shown in Fig.  1. From the 287 malaria 
children enrolled, the G6PD genotypes were available 
for only 278 children. One hundred and forty-six chil-
dren (53 %) were males. The median age was 2 (IQR: 1–4) 
years ranging from 6  months to 10  years with a mean 
haemoglobin value of 8.5 (± 2.4) g/dL.
Prevalence of G6PD genotypes and associations 
with baseline variables
Overall, 202 (73 %) children were classified as G6PD nor-
mal [type B; 114 (78 %) males, 88 (67 %) females], while 
40 (14  %) were female heterozygous (type A+) and 36 
(13  %) were G6PD deficient [type  A−; 32 (22  %) males 
hemizygous and 4 (3 %) female homozygous]. In Table 2, 
the genotype frequencies of G6PD for males and females 
Table 1 Distribution of severe malaria syndromes by study centre
Children can appear in more than one category
a Missing data for some syndromes
All (%) Lambaréné, Gabon (%) Kumasi, Ghana (%) Kisumu, Kenya (%)
Severe malaria syndromes at admissiona
 Respiratory distress 10/278 (4) 1/108 (1) 9/87 (10) 0/83 (0)
 Prostration 55/278 (20) 4/108 (4) 43/87 (49) 8/83 (10)
 Cerebral malaria 13/278 (5) 0/108 (0) 12/87 (14) 1/83 (1)
 General seizure 20/278 (7) 4/108 (4) 13/87 (15) 3/83 (4)
 Severe anaemia 26/278 (9) 5/108 (5) 20/87 (23) 1/83 (1)
 Jaundice 21/278 (8) 0/108 (0) 16/87 (18) 5/83 (6)
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by study site are shown. Between the study centres, there 
was a significant difference (p < 0.0001) in the prevalence 
of A− G6PD deficiency among males. Among females, 
the frequency of A− G6PD deficiency was lower com-
pared to males. The prevalence was 4  % in Lambaréné 
(Gabon), 5  % in Kumasi (Ghana) and 0  % in Kisumu 
(Kenya).
To investigate the association of G6PD genotypes with 
baseline variables, the children were grouped based 
on gender and G6PD genotype. Baseline demographic 
and clinical data are given in Table  3. Using a multi-
variate regression analysis adjusted for age, gender, cen-
tre, weight, temperature and parasitaemia, there was 
a significant association of the G6PD genotypes with 
the adjusted mean baseline of haemoglobin concentra-
tions (p  <  0.0001). Furthermore, a comparison between 
children G6PD normal and heterozygous (p  <  0.0001), 
and between individuals G6PD normal and G6PD defi-
cient (p  =  0.009) showed a significant difference in 
adjusted mean baseline haemoglobin. The G6PD mutant 
Fig. 1 Patient population profile
Table 2 Frequency of G6PD genotypes in malaria children from the three study centres
Data are shown as N (%). G6PD genotype: male normal = A+ or B; male hemizygous = A−; female normal = BB or BA+ or A+A+; female heterozygous = BA− or 
A+A−; female homozygous = A−A−
Country Centre Male, N B A+ A− Female, N BB BA+ A+A+ BA− A+A− A−A−
Gabon Lambaréné 52 28 (54) 9 (17) 15 (29) 56 20 (35) 14 (25) 2 (4) 1 (2) 17 (30) 2 (4)
Ghana Kumasi 46 25 (54) 8 (18) 13 (28) 41 10 (24) 11 (27) 2 (5) 1 (2) 15 (37) 2 (5)
Kenya Kisumu 48 31 (65) 13 (27) 4 (8) 35 22 (63) 7 (20) 0 (0) 0 (0) 6 (17) 0 (0)
Total 146 84 (58) 30 (20) 32 (22) 132 52 (39) 32 (24) 4 (3) 2 (2) 38 (29) 4 (3)
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genotypes were associated with a 2.7  g/dL and 1  g/dL 
decrease in haemoglobin levels in heterozygous and defi-
cient children, respectively. The multivariate regression 
analysis adjusted for age, gender, centre, weight, haemo-
globin levels and temperature did not result in any asso-
ciation (p  =  0.29) of the G6PD genotypes on adjusted 
mean baseline parasite densities. In addition, there was 
no difference in adjusted log mean parasite densities 
between G6PD normal and heterozygous individuals 
(p = 0.18), and between G6PD normal and deficient chil-
dren (p = 0.07).
Severe malarial anaemia and cerebral malaria
Following the WHO guidelines [23] which defines severe 
malarial anaemia (SMA) as Hb <5 g/dL, 26 children (9 %) 
were affected by SMA in this study. The mean haemo-
globin concentrations was 4  g/dL (range 1.9–4.9  g/dL). 
There was no difference (p =  0.66) of the haemoglobin 
levels between SMA children with different G6PD geno-
types. However, SMA occurred more frequently among 
G6PD normal 15/26 (58  %) compared to G6PD het-
erozygous 8/26 (31  %) and G6PD deficient 3/26 (12  %) 
children.
Only 13 patients (5  %) had cerebral malaria. Nine of 
them were G6PD normal and four were female G6PD 
heterozygous.
Discussion
Glucose-6-phosphate dehydrogenase deficiency has 
raised in frequencies in malaria-endemic settings as a 
consequence of the evolutionary pressure exerted by 
malaria on the human genome [16]. A plethora of pre-
vious studies have indicated and suggested a correlation 
between malaria endemicity and the occurrence of G6PD 
deficiency (reviewed in [25]).
The main objective of this study was to assess the dis-
tribution of G6PD genotypes among African children 
from three geographically countries presenting with 
severe malaria and participating in the SMAC clinical 
trial on different artesunate treatment regimens. While 
meanwhile many G6PD variants have been described [8, 
11], the main focus was on the most relevant three vari-
ants (376A (G6PD type B, no deficiency), 376G (moder-
ate G6PD deficiency type A+) and 202A severe G6PD 
deficiency type A−) in Africa [26].
The prevalence of severe G6PD deficiency as deter-
mined genetically was higher compared to previous 
findings from Gabon with 17  % in the present study 
versus 14  % reported earlier among males and 7 vs 2  % 
among females [27]. In Ghana 28  % were observed in 
this study, compared to 9  % among males and 5 vs 3  % 
among females indicated previously [28]. However, in 
Kenya the prevalence of severe G6PD deficiency among 
Table 3 Baseline demographic and clinical data following G6PD genotypes
Values are mean (SD) [range] unless otherwise indicated. G6PD genotype: male normal = A or B; male hemizygous = A−; female normal = B/B or B/A or A/A; female 
homozygous = A−/A−; female heterozygous = B/A− or A/A−
NA not applicable; SD standard deviation












Age, years [range] 3.3 (2.8) [0–10] 2.6 (2.2) [0–8] 2.2 (1.9) [0–8] 2.3 (2.6) [0–10] 2.5 (3) [0–6] 2.7 (2.5) [0–10]
0–3, n (%) 65 (57) 23 (72) 69 (78) 30 (75) 2 (50) 189 (68)
4–7, n (%) 39 (34) 8 (25) 18 (21) 7 (18) 2 (50) 74 (27)
≥8, n (%) 10 (9) 1 (3) 1 (1) 3 (7) 0 (0) 15 (5)
Weight, kg 15.6 (5.2) 12.6 (4.7) 13.2 (4) 13.2 (5.9) 16.3 (2.7) 14.1 (5)














Temperature, °C 37.9 (1.1) 38.4 (1) 38.2 (1.1) 38 (1.2) 37.7 (1.3) 38.1 (1.1)
Haemoglobin, g/dL 
(years)
8.9 (2.4) 7.8 (2.3) 8.9 (2.3) 7.1 (2.3) 8.2 (1.4) 8.5 (2.4)
0–3 8.2 (2.4) 7.6 (2.1) 8.6 (2.3) 6.7 (2.2) 8.1 (2.1) 8.1 (2.4)
4–7 9.9 (2) 8.2 (2.8) 9.7 (1.8) 6.9 (2) 8.3 (1.3) 9.3 (2.2)
≥8 9.8 (1.8) NA NA 10.6 (0.6) NA 10.2 (1.7)
Haematocrit, % 27.4 (7.3) 23.8 (7.1) 27.3 (7) 21.7 (7.6) 25.5 (4) 26.1 (7.5)
Red blood cell count, 
10^12/L
3.8 (1) 3.3 (1.2) 3.6 (1) 3 (1) 3.1 (0.4) 3.6 (1.1)
Platelet count, 10^9/L 151.6 (230.4) 98 (82) 117.3 (118.8) 111 (77.7) 63.3 (30) 127.5 (167.9)
White blood cell count, 
10^9/L
9.4 (4.2) 11.6 (7.9) 9.8 (4.3) 11.6 (4.4) 7.7 (3.4) 10.1 (4.9)
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females was lower compared to previous reports with 
0 vs 5 % and equal among males 8 vs 8 % [29]. Regard-
less of the site, G6PD deficiency was considerably higher 
among males (22 %) compared to females (3 %), with an 
overall prevalence of 13 % across sites. This finding con-
firms that males are affected by this blood disorder rather 
than females and that G6PD deficient females are rather 
uncommon [26].
A significant association of moderately and severely 
deficient G6PD genotypes and haemoglobin levels 
according to the baseline data was observed. In fact, 
compared to children with the normal G6PD genotype 
(haemoglobin median: 9.3  g/dL), G6PD heterozygous 
(haemoglobin median: 6.6 g/dL) and deficient (haemoglo-
bin median: 8.3 g/dL) children had 2.7 and 1 g/dL lower 
haemoglobin concentrations, respectively. The results 
contradict previous findings, which did not observe any 
association between G6PD genotypes and haemoglobin 
levels [30–32]. While in their study, May et al. [32] found 
lower levels of haemoglobin in G6DP deficient individu-
als, the association was not significant. An explanation 
could be the different designs of that and the present 
study. Here, patients with severe malaria were included, 
which implies high parasitaemia and haemoglobin con-
centrations  <5  g/dL, whereas in the above cited study, 
the authors excluded patients with haemoglobin concen-
trations ≤7 g/L [30] and recruited individuals only with 
uncomplicated malaria [31] or who were asymptomati-
cally infected [32].
In the case of SMA, there was no difference of hae-
moglobin levels among children with different G6PD 
genotypes. This may suggest that G6PD deficiency is 
not associated with this complication. However, this is 
in fact surprising especially as a significant difference of 
baseline haemoglobin values between G6PD normal and 
deficient individuals was observed. Moreover, in a large 
case–control study in Kenyan individuals, a significant 
increased risk to severe malarial anaemia associated with 
lower haemoglobin levels in G6PD deficient children 
with severe malaria at the time of hospital admission was 
found [33]. The likely explanation could be due to the 
sample size which was rather small.
Although not significant, parasite densities were lower 
in G6PD deficient children than in G6PD heterozygous, 
compared to G6PD normal individuals. However, this 
trend is in agreement with previous works [34, 35]. Con-
flicting results have been reported regarding parasitae-
mia and the various G6PD genotypes. Other studies have 
indicated a significantly lower parasitaemia associated 
with female G6PD heterozygous individuals, suggesting a 
protective advantage by this genotype [36–39].
In comparison to individuals with uncomplicated 
malaria, this study population was hyperparasitemic 
according to the criteria of severe malaria provided 
by WHO with lower parasitaemia in G6PD deficient 
individuals. However, either in uncomplicated or in 
severe/complicated malaria, G6PD deficiency was 
always associated with lower parasitaemia [30, 33]. 
Although the underlying genetic mechanisms are not 
completely clear, mechanisms suggested are impaired 
growth of P. falciparum parasites in G6PD deficient 
red blood cells [40] and slow rates of parasite replica-
tion [41, 42], more efficient clearance of infected red 
blood cells [43], and lower abundance of P. falciparum 
6-phosphogluconolactonase mRNA in parasites from 
G6PD deficient individuals [44] both uncomplicated 
and severe malaria.
Several limitations apply to this study. Although some 
of the observations are in agreement with previous 
findings, the study group is rather small. The focus was 
only on the G6PD mutations 202G > A and 376A > G, 
although other variants such as A542T, G680T or 
T968C have also been reported to contribute to G6PD 
deficiency, albeit at far lower frequencies. The asso-
ciations observed between G6PD genotypes and the 
baseline clinical parameters at admission could in fact 
also be the result of different circumstances. First, only 
patients with severe malaria were included, which could 
explain the findings, especially as the G6PD deficient 
allele 202A appears to confer protection against cerebral 
malaria and increases the risk of severe malarial anae-
mia [16, 17]. Second, depending on the mechanism of 
protection, G6PD deficiency might be associated with 
delayed presentation to the hospital and be a plausible 
explanation of the differences observed in haemoglo-
bin concentrations at first admission. Third, alpha-tha-
lassaemia, another haemoglobinopathy which has been 
associated with lower haemoglobin levels in alpha-tha-
lassaemic Nigerian children and adults [45] cannot be 
ruled out as a confounding variable as it was not inves-
tigated in this study. The statistical analysis using mul-
tivariable regression model is in part subjective due to 
the adjusted variables added.
Conclusions
G6PD deficiency is more common among children 
from Gabon and Ghana than in Kenya. A significant 
association of the G6PD genotypes studied to lower 
haemoglobin levels was observed, suggesting a pos-
sible contributions of G6PD deficiency to the reduced 
production of erythrocytes in affected individuals. This 
was, however, not related to severe malarial anaemia 
experienced by some children. There was no evidence 
of a significant association between lower parasitaemia 
observed in G6PD deficient individuals compared to 
normal ones.
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